In the BioHarmony Drug Report Database

"Preview" Icon

Ripretinib

Qinlock (ripretinib) is a small molecule pharmaceutical. Ripretinib was first approved as Qinlock on 2020-05-15. It is used to treat gastrointestinal stromal tumors in the USA. The pharmaceutical is active against mast/stem cell growth factor receptor Kit and platelet-derived growth factor receptor alpha. Qinlock’s patents are valid until 2040-08-12 (FDA).

 

Trade Name

 

Qinlock
 

Common Name

 

ripretinib
 

ChEMBL ID

 

CHEMBL4216467
 

Indication

 

gastrointestinal stromal tumors
 

Drug Class

 

Retinol derivatives; tyrosine kinase inhibitors

Image (chem structure or protein)

Ripretinib structure rendering